The effects of coenzyme Q10 on cerebral infarction

Effects of oral administration of ubiquinone in cerebral stroke patients on the neurologic, psycho-cognitive and oxidative stress disorders

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210907052400N2

Enrollment

Registered

2021-10-06

Start date

2021-10-12

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: Half of the patients placed in the intervention group by the researcher

After initial evaluation of the initial variables and discharge from the hospital, they begin interventional therapy, which is complementary drug therapy with coenzyme Q10. In this study, patients wil

It is 98% pure and is made in South Korea. Intervention 2: Control group: The other half of the patients included in the study will be in the control group by the researcher of this study. All evaluat

Take 3 servings of placebo capsules for 30 days. Patients who are blinded by the type of segmentation and the type of intervention

They receive a 200 mg capsule similar to the intervention capsules. The contents of the capsules of this group are filled with glucose powder.

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with acute ischemic stroke Patients who have had a stroke for the first time Patients between the ages of 20 and 80

Exclusion criteria

Exclusion criteria: Having other neurodegenerative disorders Having acute mental disorders Having liver and kidney malignancies Having rheumatism and chronic infections Taking vitamin supplements and immune boosters in the last month

Design outcomes

Primary

Measure	Time frame
Oxidative stress. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Spectroscopy (by taking a blood sample).;Sensory-motor function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using Berg Balance Scale.;Psycho-cognitive function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using the MoCA questionnaire.;Physical activity rate. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using SIMPAQ questionnaire and Barthel index.	—

Measure

Time frame

Oxidative stress. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Spectroscopy (by taking a blood sample).;Sensory-motor function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using Berg Balance Scale.;Psycho-cognitive function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using the MoCA questionnaire.;Physical activity rate. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using SIMPAQ questionnaire and Barthel index.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Khazaei

Hamedan University of Medical Sciences

khazaeimojtaba@yahoo.com+98 81 3565 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026